Pulmonary Embolism Market Report 2026

Pulmonary Embolism Market Overview

• Pulmonary Embolism market size has reached to $2.26 billion in 2025 • Expected to grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 13.1% • Growth Driver: Increasing Prevalence Of Cancer To Drive The Growth Of Pulmonary Embolism Market • Market Trend: Leading Companies In The Pulmonary Embolism Market Innovate With Advanced Catheter Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pulmonary Embolism Market?

A pulmonary embolism is a blockage in the pulmonary artery, which transports blood from the heart to the lungs. It causes the clot of blood that has gone to the lungs from another area of the body, most commonly the legs, which causes blockage. The symptoms of pulmonary embolism might range from abrupt shortness of breath to chest pain, coughing up blood or bloody mucus and others, depending on the severity of the clot. The main types of treatment for pulmonary embolism are medications, mechanical devices, surgery and others. Medications refer to substances used for medical treatment, management, prevention, or relief of various medical conditions and illnesses. It is diagnosed with various methods, such as a chest X-ray, electrocardiogram (ECG), magnetic resonance imaging (MRI), computed tomography scan, pulmonary angiography, venography, venous ultrasound, D-Dimer test and others. It has various symptoms such as shortness of breath, chest pain, cough, irregular heartbeat, dizziness, fever, cyanosis and others and its drugs are mainly distributed through hospital pharmacies, retail pharmacies, online pharmacies and others. The main end-users are hospitals, specialty clinics, homecare and others.

What Is The Pulmonary Embolism Market Growth Forecast?

The pulmonary embolism market size is expected to see rapid growth in the next few years. It will grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to increasing investments in advanced anticoagulant drugs, rising adoption of catheter-based intervention techniques, expansion of early diagnostic screening programs, growing focus on outpatient management strategies, increasing demand for personalized cardiovascular care. Major trends in the forecast period include increasing adoption of novel anticoagulant therapies, rising use of minimally invasive thrombectomy devices, growing focus on early and accurate diagnosis, expansion of integrated care pathways, enhanced emphasis on risk stratification and prevention.

Global Pulmonary Embolism Market Segmentation

1) By Treatment: Medications, Mechanical Devices, Other Treatments 2) By Diagnosis: Chest X-Ray, Electrocardiogram (ECG), Magnetic Resonance Imaging (MRI), Computed Tomography Scan, Pulmonary Angiography, Venography, Venous Ultrasound, D-Dimer Test, Other Diagnosis 3) By Symptoms: Shortness Of Breath, Chest Pain, Cough, Irregular Heartbeat, Dizziness, Fever, Cyanosis, Other Symptoms 4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels 5) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Medications: Anticoagulants, Thrombolytics 2) By Mechanical Devices: Inferior Vena Cava (IVC) Filters, Catheter-Assisted Thrombectomy 3) By Other Treatments: Surgical Embolectomy, Supportive Care

What Is The Driver Of The Pulmonary Embolism Market?

The increasing prevalence of cancer is expected to propel the growth of the pulmonary embolism market. Cancer refers to a group of diseases characterized by the uncontrolled and abnormal growth of cells in the body. Increasing cancer prevalence raises the risk of blood clots, such as pulmonary embolism, in cancer patients. This leads to greater demand for diagnostics and treatments, including specialized drugs. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. Therefore, the increasing prevalence of cancer is driving the growth of the pulmonary embolism industry.

Key Players In The Global Pulmonary Embolism Market

Major companies operating in the pulmonary embolism market are Pfizer Inc., Johnson And Johnson Private Limited, F Hoffmann La Roche Ltd., Merck And Co Inc., Novartis AG, Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, GSK plc, Abbott Laboratories, AstraZeneca plc, Medtronic plc, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Daiichi Sankyo Co. Ltd., Boehringer Ingelheim International GmbH, Mitsubishi Tanabe Pharma Corporation, Genentech Inc., Hikma Pharmaceuticals plc, Aspen Pharmacare Holdings Limited, Nippon Shinyaku Co. Ltd., Fresenius Kabi AG, Inari Medical Inc., AngioDynamics Inc., Otsuka Pharmaceutical Co. Ltd., CSL Behring GmbH, Grifols S.A., Octapharma AG, Kedrion S.p.A

Global Pulmonary Embolism Market Trends and Insights

Major companies operating in the pulmonary embolism market are focused on developing innovative products such as the Triever16 Curve catheter and the RevCore thrombectomy catheter to gain a competitive advantage. For instance, in June 2023, Inari Medical Inc., a US-based medical device company, launched the Triever16 Curve catheter and the RevCore thrombectomy catheter. This innovative Triever16 Curve catheter is designed for peripheral thrombectomy and pulmonary embolism procedures. It is highly trackable and has a pre-shaped curve for focused aspiration. The catheter also features a unique design that allows easy access to larger and more powerful 20F or 24F catheters and the RevCore thrombectomy catheter is designed to treat venous in-stent thrombosis. It is a mechanical thrombectomy device that uses a nitinol basket to capture and remove blood clots. Moreover, these catheters also improve the safety and effectiveness of pulmonary embolism procedures.

What Are Latest Mergers And Acquisitions In The Pulmonary Embolism Market?

In February 2025, Stryker Corporation, a US-based provider of medical technologies, acquired Inari Medical Inc. for an undisclosed amount. With this acquisition, Stryker aims to expand its presence in the high-growth peripheral vascular market and diversify its cardiovascular product portfolio. Inari Medical Inc. is a US-based company that provides treatments for pulmonary embolism (PE) through its FlowTriever system.

Regional Outlook

North America was the largest region in the pulmonary embolism market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pulmonary Embolism Market?

The pulmonary embolism market consists of revenues earned by entities by providing services such as medical management, thrombolytic therapy, monitoring and oxygen therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The pulmonary embolism market also includes sales of diagnostic imaging equipment, oxygen delivery devices, interventional devices, medical alert systems and pulse oximeters. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pulmonary Embolism Market Report 2026?

The pulmonary embolism market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pulmonary embolism industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.